CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
sunitinib malatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00459875
NCT00459875Phase 2Completed
CompareCT.gov

Phase II Study of Sunitinib in Patients With Metastatic Papillary Renal Cell Carcinoma

Memorial Sloan Kettering Cancer Center·interventional·Posted Apr 13, 2007·Updated Nov 26, 2015

In Brief

A Phase 2 clinical trial evaluating sunitinib malate for Kidney Cancer. Completed, enrolled 24 participants across 1 site.

Detailed Summary

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with locally recurrent or metastatic kidney cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 13, 2007
Enrollment StartMar 1, 2007
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 19.2 years ago

Interventions

sunitinib malatedrug